PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022
03 November 2022 - 1:25PM
Business Wire
Company conference call and webcast at 4:30 PM
EDT
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified
commercial-stage medical device company today announced that the
Company will host a business update conference call and webcast on
Tuesday, November 15, 2022, at 4:30 PM EDT. During the call, Lishan
Aklog, M.D., Chairman and Chief Executive Officer, will provide a
business update including an overview of the Company’s operations
and its growth strategy. In addition, Dennis McGrath, PAVmed’s
President and Chief Financial Officer, will discuss the Company’s
third-quarter 2022 financial results.
The webcast will be available live at the investor relations
section of the Company’s website at https://ir.pavmed.com/.
Alternatively, to access the conference call by telephone,
U.S.-based listeners should dial 877-407-3982 and international
listeners should dial 201-493-6780. All listeners should provide
the operator with the conference call name “PAVmed, Inc. Business
Update Conference Call” to join.
Following the conclusion of the conference call, a replay will
be available for one week and can be accessed by dialing
844-512-2921 from within the U.S. or 412-317-6671 from outside the
U.S. To access the replay, all listeners should provide the
following pin number: 13732745. The webcast will be available for
replay on the investor relations section of the Company’s website
at https://ir.pavmed.com/.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its major subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD), is a commercial-stage cancer prevention medical
diagnostics company which markets the EsoGuard® Esophageal DNA Test
and EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal
precancer to prevent esophageal cancer deaths. Lucid operates its
own CLIA-certified, CAP-approved molecular diagnostic laboratory,
LucidDx Labs and a network of Lucid Test Centers. Another major
subsidiary, Veris Health Inc., is a digital health company focused
on enhanced personalized cancer care through remote patient
monitoring using implantable biologic sensors with wireless
communication along with a custom suite of connected external
devices. The product pipeline also includes the CarpX® Minimally
Invasive Device for Carpal Tunnel Syndrome, EsoCure™ Esophageal
Ablation Device with Caldus™ Technology, which complements EsoGuard
and EsoCheck, NextFlo™ Intravenous Infusion Set, PortIO™
Implantable Intraosseous Vascular Access Device, and other earlier
stage technologies. For more information on PAVmed, please visit
PAVmed.com and follow PAVmed on Twitter, LinkedIn, and YouTube. For
more information on Lucid, please visit LucidDx.com and follow
Lucid on Twitter, and LinkedIn. For detailed information on
EsoGuard, please visit EsoGuard.com and follow EsoGuard on Twitter,
Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s and Lucid’s management, are subject to
risks and uncertainties, which could cause actual results to differ
from the forward-looking statements. Risks and uncertainties that
may cause such differences include, among other things, volatility
in the price of PAVmed’s and Lucid’s common stock; PAVmed’s Series
W and Series Z warrants; general economic and market conditions;
the uncertainties inherent in research and development, including
the cost and time required to advance PAVmed’s and Lucid’s products
to regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed’s and Lucid’s
clinical and preclinical studies; whether and when PAVmed’s and
Lucid’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s and Lucid’s products once cleared and
commercialized; PAVmed’s and Lucid’s ability to raise additional
funding as needed; and other competitive developments. In addition,
PAVmed and Lucid have been monitoring the COVID-19 pandemic and the
pandemic’s impact on PAVmed’s and Lucid’s businesses. PAVmed and
Lucid expect the significance of the COVID-19 pandemic, including
the extent of its effect on its financial and operational results,
to be dictated by, among other things, the success of efforts to
contain the pandemic and the impact of such efforts on PAVmed’s and
Lucid’s businesses. These factors are difficult or impossible to
predict accurately and many of them are beyond PAVmed’s and Lucid’s
control. In addition, new risks and uncertainties may arise from
time to time and are difficult to predict. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s and Lucid’s future operations, see Part I,
Item IA, “Risk Factors,” in PAVmed’s and Lucid’s most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after
its most recent Annual Report and Lucid’s Registration Statement
No. 333-259721 filed with the Securities and Exchange Commission.
PAVmed and Lucid disclaim any intention or obligation to publicly
update or revise any forward-looking statement to reflect any
change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221103005757/en/
Investors and Media Adrian K.
Miller PAVmed Inc. AKM@PAVmed.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Mai 2023 bis Mai 2024